The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

Satellite imagery has become a game-changer for investigative journalism, offering powerful tools to uncover hidden stories, monitor environmental changes, and expose human rights abuses. But access ...

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This approval applies to individuals who have had an inadequate response to at ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray Spravato (esketamine) as a standalone treatment for adults with treatment-resistant depression. This landmark decision ...

However, Spravato contains a different form of ketamine than the version that is used intravenously—a chemical sibling called esketamine. In the years since its approval, Spravato and ketamine ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

The main ingredient for the spray is esketamine hydrochloride, which is the “chemical cousin” of ketamine. Ketamine has been used by clinics across the U.S. to treat depression, anxiety and ...

6 The mechanism by which esketamine exerts its antidepressant effect is unknown. Backed by more than a decade of research and almost six years of real-world evidence, SPRAVATO® has proven to be a ...

Since October 2020 – when the Health Sciences Authority first authorised the sale of an esketamine nasal spray for serious depression – five psychiatrists who used the therapy on their ...

for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate ...